Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Brenipatide (LY3537031) in Healthy Participants
NCT04648865Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing LY3537031 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Day 43. Started Dec 2020; status: completed.
02
Drugs
brenipatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04648865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648865.